| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/20/2011 | CN101185627B Nilotinib sustained-release implant for treating solid tumor |
| 04/20/2011 | CN101176713B Carmustine sustained-release implantation agent for curing entity tumour |
| 04/20/2011 | CN101167728B Doxazosin-mesylate controlled-releasing tablet and preparation method thereof |
| 04/20/2011 | CN101152188B Vitamin D* solid dispersion peridium patch and method for preparing the same |
| 04/20/2011 | CN101129367B S-omeprazole solid dispersion and composition containing the dispersion |
| 04/20/2011 | CN101125124B Method for preparing lipophilic medicine solid dispersion |
| 04/20/2011 | CN101120913B Ftibamzone chrisma with PEG-200 as co-solvent |
| 04/20/2011 | CN101095681B Alfuzosin Hydrochloride permeating pump type controlled-release preparation and method for preparing the same |
| 04/20/2011 | CN101066290B Hongyao ointment and its preparation |
| 04/20/2011 | CN101053553B Biodegradable fluorourcacil polyester medicine-carried nanospheres and its preparation method |
| 04/20/2011 | CN101024090B Gene transferring compound and its preparing method |
| 04/20/2011 | CA2683248A1 Solubilized formulation of docetaxel |
| 04/19/2011 | US7928219 chemically modified nucleic acid molecule; cancer; carcinoma, neovascularization, diabetic retinopathy, neovascular glaucoma, myopic degeneration and other proliferative diseases, restenosis and polycystic kidney disease |
| 04/19/2011 | US7928218 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 04/19/2011 | US7928147 Buffer, surfactant, chelate compound, nonionic preservative microbiocide; sensitivity; wound healing agents; topical, drug delivery |
| 04/19/2011 | US7928144 Antiinflammatory and analgesic preparation for external use |
| 04/19/2011 | US7928143 Method for preventing and/or treating neurodegenerative diseases |
| 04/19/2011 | US7928075 Binding agents which inhibit myostatin |
| 04/19/2011 | US7927870 DNA vaccine formulations |
| 04/19/2011 | US7927852 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| 04/19/2011 | US7927811 Binds to cerebrovascular endothelial cell; expression vectors; micelle, liposome or microcapsule used as carriers |
| 04/19/2011 | US7927792 Targeted double stranded RNA mediated cell killing |
| 04/19/2011 | US7927628 Sustained release preparations and process for producing the same |
| 04/19/2011 | US7927626 Biocompatible liquid, biocompatible gas, and solid particles of a biocompatible polymer are mixed together to form a homogenous composition including a discontinuous gas phase with solid particles homogenously dispersed throughout a continuous liquid phase |
| 04/19/2011 | US7927624 Hydrophilic/lipophilic polymeric matrix dosage formulation |
| 04/19/2011 | US7927623 Pleasant taste; bioabsorbable; overcoated water insoluble drug in alcohol solvent and water soluble binder; mixing, compression |
| 04/19/2011 | US7927622 Methods of transnasal transport/immunization with highly adaptable carriers |
| 04/19/2011 | US7927618 Implants, particles |
| 04/19/2011 | US7927589 Non-immunognic polyethylene glycol conjugated therapeutic uricase for use in treatment of kidney and inflammatory disorders |
| 04/19/2011 | US7927581 Peptide-based multimeric targeted contrast agents |
| 04/19/2011 | CA2624788C Improved testosterone gel and method of use |
| 04/19/2011 | CA2474691C Melt extrusion of salts of active ingredients |
| 04/19/2011 | CA2474674C Solid preparation containing single crystal form |
| 04/19/2011 | CA2462338C Powder processing with pressurized gaseous fluids |
| 04/19/2011 | CA2425271C Liposomes encapsulating anticancerous drugs and use thereof in the treatment of malignant tumours |
| 04/19/2011 | CA2400969C Carbohydrate formulation (prebiotic adjuvant) for enhancement of immune response to measles vaccine |
| 04/19/2011 | CA2400886C Novel galenical form for oral administration with prolonged release of molsidomine |
| 04/19/2011 | CA2362496C Polypeptide variants with increased heparin-binding ability |
| 04/16/2011 | CA2735344A1 A novel formulation for treating fungal infections |
| 04/14/2011 | WO2011044545A2 Methods and compositions for targeted imaging |
| 04/14/2011 | WO2011044540A1 Topical formulation comprising etoricoxib and a zwitterionic surfactant |
| 04/14/2011 | WO2011044533A2 Coating system and method for drug elution management |
| 04/14/2011 | WO2011044367A1 Methods and compositions for skin regeneration |
| 04/14/2011 | WO2011044034A1 Carrageenan-containing aqueous antimicrobial compositions |
| 04/14/2011 | WO2011044008A1 Low ether composition and delivery apparatus |
| 04/14/2011 | WO2011043980A1 Methods and compositions related to clot-binding lipid compounds |
| 04/14/2011 | WO2011043695A1 Pharmaceutical composition for the prophylaxis and treatment of infectious and non-infectious diarrhoea |
| 04/14/2011 | WO2011043502A1 Composite of photosensitizer-metal nanoparticles and composition for photodynamic therapy or diagnosis comprising same |
| 04/14/2011 | WO2011043469A1 Method for efficient proliferation of kupffer cells, and use thereof |
| 04/14/2011 | WO2011043455A1 Orally administrable liquid formulation containing acetaminophen |
| 04/14/2011 | WO2011043370A1 Coating film, and granules and tablets each utilizing same |
| 04/14/2011 | WO2011042663A1 Stabilising excipient for inactivated whole-virus vaccines |
| 04/14/2011 | WO2011042542A1 Formulation of drugs and vaccines in the form of percutaneous injectable needles |
| 04/14/2011 | WO2011042463A2 Pharmaceutical composition comprising poorly soluble active ingredient and hyperbranched polymer |
| 04/14/2011 | WO2011042453A1 Subcutaneous paliperidone composition |
| 04/14/2011 | WO2011042450A1 Carrier linked paliperidone prodrugs |
| 04/14/2011 | WO2011042365A1 Method for preparing a composition comprising a compound based on vanillin and ethyl vanillin, resulting composition and uses thereof |
| 04/14/2011 | WO2011041897A1 Compositions and methods for the transport of therapeutic agents |
| 04/14/2011 | WO2011041872A1 Nitric oxide amino acid ester compounds for the prophylaxis of angina pectoris |
| 04/14/2011 | WO2011026234A8 Clarithromycin extended-release tablet |
| 04/14/2011 | WO2011020866A3 Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| 04/14/2011 | WO2011015634A3 Controlled release formulations of lipocalin muteins |
| 04/14/2011 | WO2011012850A3 Glycopolysialylation of non-blood coagulation proteins |
| 04/14/2011 | WO2011008985A3 Conjugates comprising dna-binding agent for targeted delivery of therapeutic agents |
| 04/14/2011 | WO2010147412A3 (metha)acrylate polymer, preparation method thereof and oil formulation containing the same |
| 04/14/2011 | WO2010138379A3 Methods of treating chronic neurogenic inflammation using a modified clostridial toxin |
| 04/14/2011 | WO2010131907A3 Sirna delivery system using self-assembled polymeric nanoparticles |
| 04/14/2011 | WO2010094806A3 Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes |
| 04/14/2011 | WO2010093873A3 Drug delivery through hydrogel plugs |
| 04/14/2011 | WO2010084088A3 Starch nanoparticles for drug delivery systems |
| 04/14/2011 | WO2010065730A3 Pharmaceutical suspension |
| 04/14/2011 | WO2010028489A8 Starch-based microparticles for the release of agents disposed therein |
| 04/14/2011 | WO2001085798A9 Human monoclonal antibodies to dendritic cells |
| 04/14/2011 | US20110087004 Enhanced oral transcompartmental delivery of therapeutic or diagnostic agents |
| 04/14/2011 | US20110086925 Method and System to Detect, Diagnose, and Monitor the Progression of Alzheimer's Disease |
| 04/14/2011 | US20110086924 Method of manufacturing an eutectic crystalline sugar alcohol |
| 04/14/2011 | US20110086844 Oral Solid Solution Formulation of a Poorly Water-Soluble Active Substance |
| 04/14/2011 | US20110086826 Liposomal camptothecins and uses thereof |
| 04/14/2011 | US20110086809 Enteral Administration Of Arginine-Glutamine Dipeptide To Support Retinal, Intestinal, Or Nervous System Development |
| 04/14/2011 | US20110086416 Immunotoxin fusion proteins and means for expression thereof |
| 04/14/2011 | US20110086119 Preparation for the relief of disease |
| 04/14/2011 | US20110086104 Residual solvent extraction method and microparticles produced thereby |
| 04/14/2011 | US20110086095 Bioadhesive Polymers |
| 04/14/2011 | US20110086085 Carbohydrate Entrapped Active Agent Delivery Composition and Articles Using the Same |
| 04/14/2011 | US20110086071 Pharmaceutical Compositions Comprising Terbinafine |
| 04/14/2011 | US20110086064 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 04/14/2011 | US20110086036 Composition comprising vlp and amyloid beta peptide |
| 04/14/2011 | US20110086001 Compliant biocompatible polymer compositions for medical uses |
| 04/14/2011 | US20110085988 Swollen silicone composition, process of producing same and products thereof |
| 04/14/2011 | US20110083991 Hyaluronic acid derivative and drug containing the same |
| 04/14/2011 | CA2777096A1 Compositions and methods for the transport of therapeutic agents |
| 04/14/2011 | CA2776291A1 Method for preparing a composition comprising a compound based on vanillin and ethyl vanillin, resulting composition and uses thereof |
| 04/14/2011 | CA2775747A1 Methods and compositions related to clot-binding lipid compounds |
| 04/14/2011 | CA2775603A1 Carrageenan-containing aqueous antimicrobial compositions |
| 04/14/2011 | CA2775573A1 Generation, characterization and uses thereof of anti-her 3 antibodies |
| 04/13/2011 | EP2308975A1 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof |
| 04/13/2011 | EP2308916A1 Polymer/metal complex composite having mri contrast ability and mri contrasting and/or antitumor composition using the same |
| 04/13/2011 | EP2308881A1 Isosorbide-derivatives |
| 04/13/2011 | EP2308878A2 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and use as medicaments |
| 04/13/2011 | EP2308563A1 Risedronic acid for treatment and prevention of bone resorption diseases |